CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

CHEPLAPHARM wins again

Greifswald, 05/15/2020 – The family-owned pharmaceutical company CHEPLAPHARM Arzneimittel GmbH got honoured with the highly coveted ‘Axia Best Managed Companies Award’ for the second time in a row. Thus, CHEPLAPHARM repeatedly demonstrates its innovational strength, its strategic vision and sustainable leadership culture.

"We are very proud to be honoured again", states Sebastian F. Braun, CHEPLAPHARM's CEO, "because it shows that we tied in with the achievements of the previous years and delivered an outstanding performance. CHEPLAPHARM has a fabulous team, for which I am much obliged for. Thus, we are well-equipped for the next big steps ahead."

The Axia Best Managed Companies program is a contest carried out by Deloitte, Credit Suisse and the Federation of German Industries (BDI) such as the German magazine 'WirtschaftsWoche'. Therefore, the award is a hallmark of excellence for prosperous mid-sized businesses. One of the reward’s unique characteristic is its internationality: Deloitte originated the Best Managed Companies Award in Canada in the 1990's. It was Deloitte's vision to establish a national and global network of outstandingly managed mid-sized businesses. CHEPLAPHARM now joins the list of prestigious companies like Rossmann and Develey and further emphasizes the importance of Mecklenburg-Western Pomerania as an excellent business location.

"As one of the laureates, CHEPLAPHARM convinces again with its premier corporate management – through high innovative strength, a long-ranged and forward-looking strategy and strong governance structures. CHEPLAPHARM therefore is not only a benchmark for saliently leaded mid-sized businesses, but stands allegorical for the future of the business location Germany", Lutz Meyer, partner and leader of Deloitte’s mid-sized businesses program, points out.

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com


Investor Relations topics

Back to top expand_less